Detailed information for compound 518776

Basic information

Technical information
  • TDR Targets ID: 518776
  • Name: N-benzyl-5-(3,5-dimethylpiperidin-1-yl)sulfon yl-N-ethyl-3-methyl-1-benzofuran-2-carboxamid e
  • MW: 468.608 | Formula: C26H32N2O4S
  • H donors: 0 H acceptors: 3 LogP: 5.21 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCN(C(=O)c1oc2c(c1C)cc(cc2)S(=O)(=O)N1CC(C)CC(C1)C)Cc1ccccc1
  • InChi: 1S/C26H32N2O4S/c1-5-27(17-21-9-7-6-8-10-21)26(29)25-20(4)23-14-22(11-12-24(23)32-25)33(30,31)28-15-18(2)13-19(3)16-28/h6-12,14,18-19H,5,13,15-17H2,1-4H3
  • InChiKey: ZNHNBEXEBBBFMB-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • N-benzyl-5-[(3,5-dimethyl-1-piperidyl)sulfonyl]-N-ethyl-3-methyl-benzofuran-2-carboxamide
  • N-benzyl-5-[(3,5-dimethyl-1-piperidinyl)sulfonyl]-N-ethyl-3-methyl-2-benzofurancarboxamide
  • 5-(3,5-dimethylpiperidin-1-yl)sulfonyl-N-ethyl-3-methyl-N-(phenylmethyl)-1-benzofuran-2-carboxamide
  • N-benzyl-5-(3,5-dimethylpiperidino)sulfonyl-N-ethyl-3-methyl-coumarilamide
  • 5-[(3,5-dimethyl-1-piperidyl)sulfonyl]-N-ethyl-3-methyl-N-(phenylmethyl)benzofuran-2-carboxamide
  • 5-[(3,5-dimethyl-1-piperidinyl)sulfonyl]-N-ethyl-3-methyl-N-(phenylmethyl)-2-benzofurancarboxamide
  • N-(benzyl)-5-[(3,5-dimethyl-1-piperidyl)sulfonyl]-N-ethyl-3-methyl-benzofuran-2-carboxamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens cannabinoid receptor 1 (brain) Starlite/ChEMBL References
Homo sapiens cannabinoid receptor 2 (macrophage) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Loa Loa (eye worm) thymidylate synthase 1.0455 0.8833 1
Onchocerca volvulus 0.01 0.0029 0.002
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.3327 0.2772 0.3138
Mycobacterium ulcerans thymidylate synthase 1.0455 0.8833 1
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.3327 0.2772 0.3116
Mycobacterium ulcerans phosphoribosylamine--glycine ligase 0.0453 0.0329 0.0341
Mycobacterium leprae PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) 1.0455 0.8833 1
Chlamydia trachomatis dihydrofolate reductase 0.3327 0.2772 0.5
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase 1.1828 1 1
Wolbachia endosymbiont of Brugia malayi phosphoribosylamine--glycine ligase 0.0453 0.0329 1
Mycobacterium tuberculosis Probable phosphoribosylformylglycinamidine CYCLO-ligase PurM (AIRS) (phosphoribosyl-aminoimidazole synthetase) (air synthase) 0.01 0.0029 0.0033
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase 1.1828 1 1
Echinococcus multilocularis thymidylate synthase 1.0455 0.8833 1
Mycobacterium tuberculosis Probable thymidylate synthase ThyA (ts) (TSASE) 1.0455 0.8833 1
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 1.1828 1 0.5
Brugia malayi thymidylate synthase 1.0455 0.8833 1
Trichomonas vaginalis conserved hypothetical protein 0.5063 0.4248 0.5
Onchocerca volvulus 1.0455 0.8833 1
Brugia malayi hypothetical protein 0.5063 0.4248 0.2436
Echinococcus granulosus thymidylate synthase 1.0455 0.8833 1
Mycobacterium leprae PROBABLE PHOSPHORIBOSYLAMINE--GLYCINE LIGASE PURD (GARS) (GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE) (PHOSPHORIBOSYLGLYCINAMIDE SYNT 0.0453 0.0329 0.0341
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.3327 0.2772 0.3116
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 1.1828 1 0.5
Schistosoma mansoni bifunctional dihydrofolate reductase-thymidylate synthase 1.0455 0.8833 1
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 1.1828 1 0.5
Mycobacterium tuberculosis Hypothetical protein 0.5063 0.4248 0.481

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 95 % Inverse agonist activity at human CB1 receptor by [35S]GTPgammaS incorporation assay relative to rimonabant ChEMBL. 19520572
EC50 (functional) = 435 nM Inverse agonist activity at human CB1 receptor expressed in HEK293 EBNA cells by [35S]GTPgammaS incorporation assay ChEMBL. 18083560
EC50 (functional) = 435 nM Inverse agonist activity at human CB1 receptor expressed in HEK293 EBNA cells by [35S]GTPgammaS incorporation assay ChEMBL. 18083560
EC50 (functional) = 0.3 uM Inverse agonist activity at human CB1 receptor by [35S]GTPgammaS incorporation assay ChEMBL. 19520572
Inhibition (binding) = 98 % Displacement of radioligand from human CB1 receptor expressed in HEK293 cells at 10 uM ChEMBL. 18083560
Inhibition (binding) = 98 % Displacement of radioligand from human CB1 receptor expressed in HEK293 cells at 10 uM ChEMBL. 18083560
Ki (binding) = 92 nM Displacement of radioligand from human CB1 receptor expressed in HEK293 cells ChEMBL. 18083560
Ki (binding) = 92 nM Displacement of radioligand from human CB1 receptor expressed in HEK293 cells ChEMBL. 18083560
Ki (binding) = 3100 nM Displacement of radioligand from human CB2 receptor expressed in HEK293 cells ChEMBL. 18083560
Ki (binding) = 3100 nM Displacement of radioligand from human CB2 receptor expressed in HEK293 cells ChEMBL. 18083560
Ratio Ki (binding) = 34 Selectivity ratio, Ki for human CB2 receptor to Ki for human CB1 receptor ChEMBL. 18083560

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.